Taking the points one by one...
"First of all the "chines herb" used in this "miracle drug" has been around for centuries. It is just being repackaged to try and mislead its use now."
Interesting. The foxglove plant has also been around for a long time and in the late 1700s was noted to have some medicinal effects. Later study identified that it helped cardiac contractility by acting on sodium channels. It had to be "repackaged" for use as a drug because while it worked, foxglove extract as a herb had a narrow therapeutic index (the dose where it became toxic was too close to the dose where it worked effectively in therapy for increasing heart contractility) and it was difficult to tell how much active ingredient was present in the herbal preparation. Therefore the active ingredient was extracted and used in Digoxin the drug currently in use.
With regard to Sucanon, the previous article that I cited from sucanonhealth.com pointed out that the particular combination (then studied in China and later in Brazil), was noted by accident to have strong blood sugar lowering properties. When the preclinical studies were done in late 1990's the substance was noted to be effective with a very large therapeutic index (margin of safety between effective dose and toxicity of >10,000). Clinical studies in China Brazil and Mexico during about 1997 to 2003 showed superior clinical efficacy to Glyburide (details have been posted here repeatedly) and were the basis for Mexican government approval for sale of Sucanon. (The results have also been available and published long before Irving, Hall, Dr. Jiminez or any of the people you have indicated issues with their involvement in the company and issues about these studies being conflicted because of Dr Jiminez current work for the company are without any possible logical basis) . The science on Sucanon is very impressive and can be verified publicly.
"Secondly the FDA recognized this Chinese herb when citing its denial to this "drug" The FDA reviewed PharmaRoth’s NDI and concluded that Sucanon’s active ingredient would be inappropriately classified as a neutraceutical. The application was therefore denied."
The argument gets mixed up here. ROTH did not submit a NDI (investigational new drug application). It submitted as a neutraceutical citing the herbal origins. FDA did deny Sucanon use as a neutraceutical because they considered Sucanon a drug and therefore would need a NDI application prior to consideration for sale in the US. Currently Sucanon is sold in Similares pharmacias throughout Mexico and has been approved for sale as of late 2015 in Canada.
There is still the concern that in a recent post that you left out a paragraph from an otherwise quoted Consumer reports article on herbal preparations to make it sound like a warning somehow applied to Sucanon when it did not. "OldBiohfguy" has actually asked for clarification of that point multiple times yet there has been no response. Perhaps your next post could clear that up. Thanks in advance
